Comparative Transcriptome Analysis Reveals Stem Secondary Growth of Grafted Rosa rugosa 'Rosea' Scion and R. multiflora 'Innermis' Rootstock.

Grafted plant is a chimeric organism formed by the connection of scion and rootstock through stems, so stem growth and development become one of the important factors to affect grafted plant state. However, information regarding the molecular responses of stems secondary growth after grafting is limited. A grafted Rosa plant, with R. rugosa 'Rosea' as the scion (Rr_scion) grafted onto R. multiflora 'Innermis' as the stock (Rm_stock), has been shown to significantly improve stem thickness. To elucidate the molecular mechanisms of stem secondary growth in grafted plant, a genome-wide transcription analysis was performed using an RNA sequence (RNA-seq) method between the scion and rootstock. Comparing ungrafted R. rugosa 'Rosea' (Rr) and R. multiflora 'Innermis' (Rm) plants, there were much more differentially expressed genes (DEGs) identified in Rr_scion (6887) than Rm_stock (229). Functional annotations revealed that DEGs in Rr_scion are involved in two Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways: the phenylpropanoid biosynthesis metabolism and plant hormone signal transduction, whereas DEGs in Rm_stock were associated with starch and sucrose metabolism pathway. Moreover, different kinds of signal transduction-related DEGs, e.g., receptor-like serine/threonine protein kinases (RLKs), transcription factor (TF), and transporters, were identified and could affect the stem secondary growth of both the scion and rootstock. This work provided new information regarding the underlying molecular mechanism between scion and rootstock after grafting.

Role of Aliphatic Chain Characteristics on the Anti-Cracking Properties of Polymer-Modified Asphalt at Low Temperatures.

The anti-cracking properties of polymer-modified asphalt depend largely on the molecular structure of the polymer modifier. However, the mysterious structure-performance relationship is still elusive. In this paper, three kinds of polymers with different chain structures were selected to address this issue. The indices of styrene, trans-butadiene, aliphatic branched-chain, and aliphatic long-chain from the infrared spectrum were used to quantify the functional group compositions of polymer modifiers. Viscoelastic parameters, including relaxation time, dissipation energy ratios, and stiffness were assessed to illustrate the anti-cracking properties of polymer-modified asphalt. Results showed that relaxation time and dissipation energy ratios were mainly determined by the polymer network strength, molecular size, aliphatic chain feature, and the orientations speed of aliphatic chains. The short relaxation time and high dissipation ratio lead to the low stiffness and favorable low-temperature performance of asphalt. The improvement of these performances requires a polymer with high indices of an aliphatic long-chain, styrene, aliphatic branched-chain, and trans-butadiene, respectively. An aliphatic-long chain, aliphatic branched-chain, and trans-butadiene were soft segments in asphalt while styrene was the rigid segment. The soft segments affect the intramolecular friction, orientation, and thermal motion at low temperatures, whereas the rigid segment enhances the strength of polymer networks. Thus, the anti-cracking property of polymer-modified asphalt can be improved by adjusting the ratio of soft and rigid segments in the polymer modifier.

Measurement of serum antibodies against NY-ESO-1 by ELISA: A guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer.

NY-ESO-1 has been identified as one of the most immunogenic antigens; thus, is a highly attractive target for cancer immunotherapy. The present study analyzed the expression of serum antibodies (Abs) against NY-ESO-1 in patients with advanced colorectal cancer (CRC), with the aim of guiding the treatment of NY-ESO-1-based specific-immunotherapy for these patients. Furthermore, the present study was the first to evaluate the kinetic expression of anti-NY-ESO-1 Abs and investigate the possible influencing factors. A total of 239 serum samples from 155 pathologically confirmed patients with advanced CRC (stages III and IV) were collected. The presence of spontaneous Abs against NY-ESO-1 was analyzed using an enzyme-linked immunosorbent assay (ELISA). The results demonstrated that 24.5% (38/155) of the investigated patients were positive for NY-ESO-1-specific Abs. No statistically significant correlations were identified between the expression of anti-NY-ESO-1 Abs and clinicopathological parameters, including age and gender, location, grading, local infiltration, lymph node status, metastatic status and K-ras mutation status (P>0.05). In 59 patients, the kinetic expression of anti-NY-ESO-1 Abs was analyzed, of which 14 patients were initially positive and 45 patients were initially negative. Notably, 16/59 (27.1%) patients changed their expression status during the study period, and the initially positive patients were more likely to change compared with the initially negative patients (85.7 vs. 8.8%; P<0.001). Therefore, monitoring serum Abs against NY-ESO-1 by ELISA is an easy and feasible method. The high expression rate of NY-ESO-1-specific Abs in CRC patients indicates that measuring the levels of serum Abs against NY-ESO-1 may guide the treatment of NY-ESO-1-based specific immunotherapy for patients with advanced CRC.